THM Capital Advisory advises Advanced Life Solutions on its €4.5 million Series A

THM Capital Advisory is supporting Advanced Life Solutions in its €4.5M Series A to accelerate the development of Perla® in transplantation. Advanced Life Solutions (ALS) announces the completion of the first phase of its Series A, with the support of THM Capital Advisory.

ALS is developing Perla®, a new patented liquid for the preservation and protection of grafts, aimed at improving the functional recovery of transplanted organs and their lifespan.

Founded by Silvina Ramella, an internationally recognized scientist in organ transplantation and former director of one of the main European companies in the sector, ALS was created in order to market an innovative formulation developed and patented by the University of Barcelona.

Perla® was designed to respond to the evolution of transplants, by helping to better protect more fragile grafts, especially from older donors.

ALS also points out that the preservation fluids currently used in transplant services have existed for 20 to 35 years and are less and less adapted to this type of more “sensitive” organ.

After a €1.8 million seed round with private investors and the BPI, which made it possible to carry out preclinical trials as well as a first clinical safety trial, ALS concludes a €4.5 million Series A with two family holdings, Pharmanet and Cantrak.

The objective of this round is to finalize the obtaining of the CE mark and to obtain FDA approval in the United States.

Perla® is the first step in deploying a broad range of solutions, with two other projects under development to improve the protection of transplanted organs.

THM Capital Advisory supported the managers of Advanced Life Solutions as financial advisor, and McDermott Will & Emery (Henri Pieyre de Mandiargues, Louis Feuillée) acted as legal advisor.